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ABSTRACT 
Purpose  
To review the current literature and discuss potential future roles of the novel positron emission 
tomography (PET) tracers targeting the prostate specific membrane antigen (PSMA) in patients 
with castration resistant prostate cancer (CRPC). 
Methods 
A literature search on February 19th 2018 was conducted using the Medline database and 
www.clinicaltrials.gov. Additionally illustrative cases of CRPC patients from our own 
institution who were restaged and treated based on PSMA-PET scan results are provided. 
Results 
11 studies met the inclusion criteria. PSMA-PET detected more metastatic lesions compared to 
conventional bone scan. Several patients were up-staged from non-metastatic CRPC 
(nmCRPC) to metastatic CRPC (mCRPC). Currently no clear consensus exists regarding 
treatment response assessment in PSMA-PET scans for mCRPC patients undergoing treatment. 
Also the role of PSMA-PET as a gatekeeper for systemic therapy or radioligands is currently 
undefined. PSMA-guided metastasis-directed radiotherapy may not only alleviate local 
symptoms but has the potential to defer systemic treatment in patients with oligoprogressive 
CRPC. 
Conclusion 
Compared to bone scan, PSMA-PET is more sensitive and specific to detect metastases but the 
therapeutic consequences of PSMA-PET results in the setting of CRPC remain unclear. Until 
future studies define the role of PSMA-PET in patients with CRPC, the current standard for 
imaging remains bone scan and computerized tomography. 
 
Keywords: Prostatic Neoplasms, CRPC, Positron Emission Tomography Computed 
Tomography, review, (68)Ga-PSMA 
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INTRODUCTION 
The introduction of the new positron emission tomography (PET) tracers targeting the prostate 
specific membrane antigen (PSMA) in combination with cross-sectional imaging modalities, 
namely magnetic resonance imaging (MR) or computerized tomography (CT), is changing the 
treatment landscape of prostate cancer (PC) dramatically. In patients with biochemical 
recurrence after radical prostatectomy or radiotherapy, PSMA PET/CT showed promising 
detection rates of 58% and 76% for PSA ranges of 0.2-1 and 1-2 ng/mL respectively [1]. 
Therefore, current guidelines recommend PSMA-PET-CT for early detection of recurrence to 
allow targeted salvage treatment options [2].  
 
Despite a growing body of evidence demonstrating the diagnostic superiority of PSMA-PET 
compared to CT or MRI and bone scan to identify metastases, the therapeutic consequences of 
PSMA-PET for staging in localized PC remains unclear. Conventional cross sectional imaging 
has a very limited sensitivity [3], since up to 80% of the lymph node metastasis are smaller 
than the recommended cut-off for pelvic lymph nodes of 8 mm [4]. PSMA-PET has been shown 
to detect metastases < 8mm resulting in a significantly higher sensitivity to detect lymph node 
[5] and bone metastases [6]. However, the therapeutic consequences for patients with localized 
prostate cancer and small PSMA-PET positive lesions remains unclear and is currently 
investigated, for example in the ongoing ProPSMA study (Australian New Zealand Clinical 
Trials Registry 12617000005358). As a consequence, current guidelines still recommend cross 
sectional imaging either by CT or MR and a bone scan in patients with primary diagnosis of 
intermediate to high risk PC [2].  
  
In patients with castration-resistant PC (CRPC), cross sectional imaging by either CT or MR 
and bone scan are still the recommended staging modalities (Table 1) [7-9]. As a consequence, 
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most clinical trials for patients with CRPC currently require staging with cross sectional 
imaging by either CT or MR and bone scan [10-17]. Bone scans are widely available at low 
costs, but only a 2-dimensional (2D) assessment is provided routinely [18]. It can be enhanced 
with a detailed 3-dimensional (3D) acquisition in combination with CT for exact anatomic 
localization and improved characterization using single photon emission tomography with CT 
(SPECT/CT) [19].  However, costs and time for whole body SPECT/CT are higher, compared 
to standard bone scans. 
 
The introduction of PSMA-PET for patients with CRPC as a staging modality may provide 
higher sensitivity/specificity and 3D lesion localization compared to CT or MRI and bone scan, 
but also raises many questions. First, a higher sensitivity would result in a shift from men who 
were previously found to have non-metastatic castration resistant (nmCRPC) according to bone 
scan into a metastatic CRPC (mCRPC) disease state, which would influence treatment decision 
making, resulting in earlier treatment and, second, exclude certain treatment options. Third, 
PSMA-PET would alter the definition of response to treatment and disease progression. Fourth, 
3D anatomical lesion assessment would allow metastasis-directed therapy for oligometastatic 
CRPC.  
The aim of this review was to give an overview of the potential future role of PSMA-PET in 
patients with CRPC in the current literature and to provide patients examples from our own 
experience. 
 
METHODS 
We conducted a literature search on February 19th 2018 using the Medline database and 
www.clinicaltrials.gov. For our literature research, we used combinations, synonyms and 
related search terms to “castration resistant prostate cancer” and “PSMA PET”. The following 
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search terms were used: prostate AND PET AND PSMA AND ("castration resistant" OR CRPC 
OR abiraterone OR enzalutamide OR docetaxel OR cabazitaxel). Non-English literature, 
animal studies, case reports, reviews, congress abstracts and correspondence/letters were 
excluded. Only studies reporting the diagnostic use of PSMA in PET were included. Two 
authors (CDF and IAB) independently screened the title and abstract of citations. The full texts 
of potentially eligible publications were obtained and disagreements were resolved by 
discussion. The reference lists of retrieved manuscripts were also screened for further eligible 
publications. 
  
To provide examples of potential roles of PSMA-PET in patients with CRPC, we identified 
CRPC patients who were restaged with a PSMA-PET at our institution between 04/2016 and 
03/2018. Informed consent was obtained from all patients and the study protocol was approved 
by the Cantonal Zurich Ethics Committee (metaPROC Study KEK-ZH-No. 2014-0007). 
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RESULTS AND DISCUSSION 
Eligible studies 
The initial search identified 57 studies of which eleven cohort studies that were published 
between 2015 and 2017 met the inclusion criteria (Table 2). One suitable study was excluded 
because the cohort was not described sufficiently [20]. 
 
PSMA-PET as staging procedure 
The introduction of PSMA-PET challenges the sensitivity/specificity of bone scan and leads to 
an earlier detection of metastases, which may trigger earlier treatment. We identified 4 
published studies comparing bone scan with PSMA-PET in CRPC cohorts. Pandit-Taskar et al. 
compared an antibody targeting PSMA (89Zr-J591), with FDG-PET, bone scan and cross-
sectional imaging in 50 patients with CRPC of which 34 patients were also biopsied [21]. The 
lesions detected by PSMA-PET and bone scan had a concordance of 89%. No overlap was 
observed in 236 lesions of which 189 were PSMA-PET positive and bone scan negative and 
37 PSMA-PET negative but bone scan positive. Of 22 biopsied bone lesions, PSMA-PET 
correctly identified 18/19 metastases and 2/2 non-metastatic sites. Of 25 biopsied soft tissue 
sites, PSMA-PET correctly identified 14/22 metastatic sites.  
 
Rowe et al. included 8 CRPC patients and compared bone scan and PET with a 18F labeled 
small molecule (18F-DCFBC) targeting PSMA [22]. The estimated proportion of all detected 
metastatic lesions that would be positive with PSMA-PET but negative or equivocal with bone 
scan was 0.31 (95% CI 0.14-0.57). The estimated proportion of lesions that would be positive 
on bone scan but negative or equivocal on 18F-DCFBC PET was 0.09 (95% CI 0.05–0.17). A 
similar study from the same institution looking at the detections rate of 18F-DCFBC PET for 
staging and response assessment is currently ongoing (NCT02856100). Next, Pyka et al. 
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compared the first 68Ga labeled PSMA targeting PET tracer (68Ga-PSMA-11) with bone scans 
in a cohort of 126 patients including 40 patients with advanced CRPC [6]. Both, PSMA-PET 
and bone scans identified all patients as mCRPC. As no biopsies were performed, the authors 
used a best valuable comparator and concluded that PSMA-PET compared to bone scans 
showed a significantly higher discriminatory accuracy (AUC of 0.993 vs. 0.945 p < 0.001). 
Compared to conventional cross-sectional imaging PSMA PET has a superior sensitivity for 
lymph node and bone metastasis. In summary, although all four studies reported that PSMA 
PET has a superior sensitivity for lymph node and bone metastasis, only one study [21] 
evaluated the diagnostic accuracy of PSMA PET with histological confirmation. 
 
PSMA-PET as a triage tool for CRPC treatment options 
PSMA-PET may not only trigger earlier treatment but might also be useful to triage the various 
treatment options for patients with mCRPC. The ALSYMPCA trial, which led to the approval 
of 223-Ra-dichloride included only patients with two or more bone metastases and no known 
visceral metastases according to bone scan and cross-sectional imaging [23].  If PSMA-PET 
instead of bone scan would be used as a staging tool for CRPC, the detection of visceral 
metastases will probably be higher compared to conventional imaging including CT or MRI 
and bone scan. As 223-Ra-dichloride is only approved for patients with mCRPC with the above 
mentioned inclusion criteria, newly detected metastases may prohibit patients to receive 223-
Ra-dichloride (see Case 1). For example, in the study of Brauer et al. 27 mCRPC patients with 
bone-only metastases according to bone scan turned out to harbor visceral metastasis in 15% 
when a PSMA PET scan was performed [24]. Similar results were reported in a Chinese patient 
population [25]. 
 
Case 1: 75 year old man with CRPC and known lymph node and bone metastases undergoing 
restaging with PSMA PET because of a rising PSA (252 ng/ml). On coronal (A) maximum 
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intensity projection disseminated intense uptake in the entire skeleton is visible. Axial CT 
images show the extensive sclerosis (B), corresponding to increased uptake on the fused PSMA 
PET/CT (C). A minimally enlarged suprarenal gland on the left would probably not have been 
reported as suspicious lesion on CT (yellow arrow) (D), however the intense PSMA 
accumulation suggested suprarenal gland metastasis (E). 
 
Furthermore, PSMA-PET may serve as a triage tool for radioligand therapy. For example 
Ahmadzadehfar et al. suggested that patients who were staged with PSMA-PET-CT before 
223-Ra-dichloride were more likely to respond compared to patients without prior PSMA-PET-
CT [26]. Although this represents an interesting hypothesis, this trial used PSA response as the 
only outcome and the different response between the groups could be caused by confounders 
alone. 
 
While 223-Ra-dichloride is active in all sclerotic osseous sites, PSMA-targeting molecules 
might only be active in PSMA-expressing tumors. PSMA-PET is currently used to select 
patients for 177Lu-PSMA therapy in most centers, with high PSMA expression in the metastasis 
being the most important selection criterion for internal radiotherapy[27,28]. Therefore, 
another hypothesis would be that PSMA-PET should predict treatment response to PSMA-
targeting molecules. However this hypothesis was not confirmed by Ferdinandus et al., who 
reported that several clinicopathological variables but no single PSMA-PET obtained variable 
was predictive for PSA response during 177Lu-PSMA therapy [29]. Overall, PSMA seems to be 
an interesting tool to improve treatment selection in CRPC. However future studies are 
necessary to elucidate if treatment selection according to PSMA-PET scan results will translate 
into survival benefits. 
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PSMA-PET for response assessment  
The best established and widely accepted criteria for treatment response assessment in cancer 
are the response evaluation criteria for solid tumors (RECIST) [30]. Sonpavde et al. could show 
that progressive disease on CT based on RECIST is prognostic for patients with metastatic PC 
[31]. However, RECIST is of limited use for PC, since bone lesions can be considered as target 
lesions, only if they have a soft tissue component of > 1 cm, and lymph nodes need a short axis 
diameter of > 1.5 cm. To further incorporate bone scan results, the Prostate Cancer Clinical 
Trials Working Group 3 (PCWG3) published a modified response assessment recommendation 
including RECIST 1.1 based on CT or MRI and bone scans [8]. Because a more sensitive and 
specific diagnostic tool like PSMA-PET may alter response assessments substantially, further 
studies defining the role of new PET-tracers for response assessment in patients with CRPC are 
of utmost importance. 
 
Guidelines for the use of PET for response assessment only exist for FDG, the most widely 
accepted criteria are the EORTC recommendations from 1999 and the PET Response Criteria 
in Solid Tumors (PERCIST), that are closely related to RECIST [32]. FDG accumulation in 
solid tumors is a measure for metabolic tumor activity and therefore a good tool to assess 
response to therapy. PSMA PET on the other hand is targeting the transmembranous protein 
PSMA. Little is known about the effect of treatment on the regulatory mechanisms of PSMA 
expression. First in vitro results of our institution show that exposure of PC cell lines to anti-
androgen therapy in fact increases PSMA expression [33]. Therefore, careful evaluation of 
PSMA PET for treatment response assessment regarding time point of imaging and also 
selection of the best representative measure will be necessary.  
 
Only one study reported the results of PSMA-PET-CT scans before and after 3 cycles of 
docetaxel in 16 men with CRPC [34]. The authors compared PSA response with either response 
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on PSMA-PET or on CT scans. Outcome prediction was concordant between PSA response 
and PSMA-PET results in nine of 16 patients (56%) but only in four of 12 patients (33%) when 
assessed by CT. 
 
PSMA-PET may also represent a gatekeeper for 223-Ra-dichloride treatment and serve as a 
promising response assessment tool for radioligand therapy. Although the ALSYMPCA trial 
demonstrated an overall survival benefit, many clinicians and patients are concerned about 
rising PSA values during treatment with Ra-223-dichloride. PSMA-PET based response 
assessment during radioligand therapy may offer an objective assessment tool, which may help 
to observe treatment response despite rising PSA levels and calm clinicians and patients.  
 
This hypothesis was supported in the reviewed literature by Ahmadzadefar et al., who argued 
that PSMA-PET-CT could represent not only a better tool for patient selection as discussed 
above, but also superior to PSA to assess treatment response after Ra-223-dichloride [26]. In a 
cohort of patients with CRPC undergoing 223-Ra-dichloride treatment, Bieth et al. identified 
31 patients who had PSMA-PET and bone scan respectively. Whereas bone scans were used to 
calculate the bone scan index (BSI), the authors used PSMA-PET-CT images to calculate two 
new indices incorporating the percentage of bone volume (BPIVOL) and average SUV (BPISUV). 
Because of the limited sample size and lack of clinical endpoints those developments have to 
be validated in future studies. Therapy response assessment with PSMA PET might help to 
assess response in selected situations. However, careful evaluation of different drug effects on 
tracer expression will be necessary for integration of PSMA expression into response 
assessments.  
  PSMA-PET targeted local and metastasis-directed therapy in the oligoprogressive CRPC patient 
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Encouraging results of local or metastasis-directed therapy in patients with hormone-naïve 
oligometastatic recurrent PC [35,36] raise the question if oligoprogressive mCRPC patients 
may also benefit from local and/or metastasis-directed therapy [37-39]. Although it remains 
unclear if oligoprogressive CRPC patients represent a distinct biological entity or whether the 
PSMA-positive lesions are just a snapshot of a systemic disease, the improved sensitivity 
resulting in an earlier detection and the 3D localization of oligoprogressive disease may offer 
a window of opportunity. In the study of Guler et al., 10 CRPC patients treated with intensity-
modulated and image-guided radiotherapy showed a progression free survival (PFS) of 0% at 
12 months [40]. Similarly Muldermanns et al. reported a biochemical PFS of 54% and a distant 
PFS of 45 % at 16 months [39]. For CRPC patients with progressive disease in the locally 
untreated prostate, Aizawa et al. showed that radiotherapy of the prostate can achieve al long-
term effect with a 8year clinical failure-free survival of 51% and a 8year relapse-free-survival 
of 26% by treatment of the pelvis [41]. Median duration to recurrence after RT was 19 months. 
Local relapse free survival was 91% after 8 years. Overall, PSMA-PET targeted radiotherapy 
in oligoprogressive mCRPC is still controversial and needs further investigation.  Our cases 2-
4 illustrate the concept of target-directed therapy in patients with oligoprogressive mCRPC.  
 
While delaying exposure to systemic therapy in patients with CRPC reduces the exposure of 
patients to treatment-related toxicity, and from a payer perspective delays expensive systemic 
therapies, it is still unknown whether this translates into a clinical benefit for patients (i.e. 
quality of life, overall survival). Indeed, local and metastasis-directed therapy in the 
oligoprogressive CRPC patient might even be harmful by postponing the use of systemic 
treatments. Therefore, image-guided therapies should be used as adjuncts rather than being 
used instead of systemic treatment. 
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Case 2: Example of PSMA-PET targeted metastasis-directed therapy in the 
oligoprogressive setting: History of radical prostatectomy 2006 and salvage radiotherapy 
03/07 with 66 Gray. He received ADT from 03/13 to 03/16, with a rise in PSA from 0.9 ng/ml 
(07/15) to 6.7 ng/ml (02/16). On coronal (A) and sagittal (B) maximum intensity projection of 
PSMA PET (06/16) a focal uptake in the third lumbar vertebra is seen. Fused axial PET/CT 
images shows the increased uptake (C), corresponding to a focal sclerosis (D, yellow arrow). 
Note that a second sclerotic lesion in the 8th thoracic vertebra was PSMA negative (E), despite 
dense sclerosis on CT (F, green arrow). Stereotactic body  radiotherapy with 48.5 Gray in 10 
fractions to the PSMA positive bone lesion was performed without additional systemic 
treatment and until now, 15 months later, the PSA is unmeasurable. This case does not only 
illustrate the high tumor to back ground ratio of PSMA PET for bone lesions, but also the 
superior specificity compared to CT and the potential of PSMA-guided metastasis-directed 
therapy in the CRPC setting. 
 
 
 
Case 3: Example of PSMA-PET targeted metastasis-directed therapy in the 
oligoprogressive setting: A 70 year old patient with CRPC since 12/2016. History of a robot-
assisted laparoscopic radical prostatectomy of a pT2c cN0 cM0 Gleason 4+3=7b R0 resected 
prostate tumor. Postoperative, a serum PSA nadir of 0.4ng/ml was reached 6 weeks after 
prostatectomy. With serum PSA-levels rising to 0.63ng/ml, a robot-assisted laparoscopic pelvic 
lymphadenectomy was performed in 2009 (pN0). In 2014 the serum-PSA-level rose to 
37.2ng/ml. A Choline-PET showed bone- and lymph node metastases (A). An antiandrogen 
therapy with Goserelin was started 06/2014. In 06/2016, PSA-levels started to rise despite 
Goserelin, and a CRPC-status was reached in 12/2016. In 11/2017, at a PSA-level of 3.8ng/ml, 
PSMA-PET-CT was performed, that showed a recurrence of the bone metastasis in the right 
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pubic bone, but no other metastases (B-D). A stereotactic radiotherapy to the bone metastasis 
was performed with 30 Gy in 5 fractions(E). Three months after treatment, the PSA-level was 
reduced to 1.4ng/ml. This case illustrates the accuracy of PSMA-PET showing active 
metastases, and gives an example of how oligoprogressive lesions can be locally irradiated to 
postpone second line systemic therapy. 
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Case 4: Example of PSMA-PET targeted therapy of the oligoprogressive primary tumor 
in the CRPC-setting: A 70 year old patient with CRPC since 07/2016. First diagnosis of 
synchronous metastatic cT3b cN1 cM1 Gleason 4+5=9 prostate cancer, with bone and lymph 
node metastases in 05/2015. The serum PSA at first diagnosis was 332 ng/ml. A Choline-PET 
(A) showed multiple pelvic lymph node metastases and bone metastases. The patient received 
leuprorelin and reached a PSA-Nadir of 15 ng/ml in 12/2015. In the following year PSA rose 
again. On PSMA-PET in 09/16 the lymph node and bone metastases still showed a good 
response without any PSMA-expression. The prostate however, showed intense PSMA-
accumulation (B). The patient was observed until PSA rose to 27 ng/ml and a new PSMA-PET 
(C-E) demonstrated still only a PSMA-PET avid local prostate cancer, without any activity in 
the previous bone- and lymph node metastases sites. The prostate and seminal vesicles were 
irradiated with 76.2Gy in 33 fractions in 10/2017 (F) and 3 months later, PSA dropped 
significantly to 1.21 ng/ml. The patient experienced no side effects of the irradiation. This is 
an interesting example of an oligoprogressive CRPC patients in which potentially only the 
primary tumor became resistant to ADT. 
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CONCLUSION 
The improved sensitivity and specificity of PSMA-PET to detect metastases has the potential 
to change the treatment landscape of patients with CRPC dramatically. The current literature 
provides mostly retrospective, small cohort studies with clinically questionable outcomes. 
Therefore, further studies are urgently needed to verify if the introduction of PSMA-PET will 
result into improved outcomes. Until further data is available, conventional imaging including 
CT or MRI and bone scan remains the gold standard for patients with CRPC. 
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Table 1 Current guideline and consensus recommendations regarding imaging for patients with 
castration resistant prostate cancer 
Guideline Recommended imaging modality 
EAU/ESTRO/ESUR/SIOG 
2018 
Bone scan and CT of chest abdomen and pelvis 
NCCN 2018 “…chest CT, bone imaging, and abdominal CT or MRI with or without 
contrast. Consider C-11 choline PET/CT or PET/MRI or F-18 fluciclovine  
PET/CT or PET/MRI for further soft tissue evaluation  or F-18 sodium 
fluoride PET/CT for further bone evaluation. 
APCCCP 2017 “…74% of the panel voted for CT and bone scintigraphy and 24% of the 
panellists voted for one of the next generation imaging methods.” 
“For monitoring of patients with a diagnosis of aggressive variant 
mCRPC, 62% of the panellists voted for standard imaging by CT and 
bone scintigraphy, 2% voted for CT alone, and 36% voted for next-
generation imaging modalities.” 
 
Table 1 Summary of included studies 
Author or 
ClinicalTrials.gov 
Identifier 
Year Sample 
Size 
Results Limitations PSMA tracer 
PSMA as staging procedure 
Pandit-Taskar [1] 2015 50 Lesions detected by PSMA-PET and bone scan had a concordance of 89%. No 
overlap was observed in 236 lesions of which 189 were PSMA-PET positive and 
bone scan negative and 37 PSMA-PET negative but bone scan positive. Of 22 
biopsied osseous sites, PSMA-PET correctly identified 18/19 metastases and 
2/2 non-metastatic sites. Of 25 biopsied soft tissue sites, PSMA-PET correctly 
identified 14/22 metastatic sites 
Limited 
number of 
biopsied 
metastases 
89Zr-J591 
Rowe [2] 2016 8 The estimated proportion of all detected metastatic lesions that would be 
positive with PSMA-PET but negative or equivocal with bone scan was 0.31 
(95% CI 0.14-0.57) 
The estimated proportion of lesions that would be positive on bone scan but 
negative or equivocal on 18F-DCFBC PET 0.09 (95% CI 0.05–0.17. 
No 
histological 
confirmation 
18F-DCFBC 
Pyka [3] 2016 40 Authors used a “best valuable comparator” and concluded that PSMA-PET 
compared to bone scans showed a significantly higher discriminatory accuracy 
(AUC of 0.993 vs. 0.945 p < 0.001). 
No 
histological 
confirmation 
68Ga-PSMA-11 
 
NCT02856100  20 Ongoing trial comparing metastatic lesions detected on PSMA-PET/CT at 
baseline and follow-up with standard of care conventional imaging (CT and 
bone scan) response at 8-12 weeks 
 18F-DCFBC 
 
PSMA-PET as a gate keeper 
Brauer [4] 2017 27 Bone-only metastases according to bone scan turned out to harbor PSMA avid 
visceral metastases in 15% of all patients 
Retrospective 
cohort study 
68Ga-PSMA-11 
Zang[5] 2017 15 Newly detected visceral metastasis in a subset of CRPC patients  Not clear if in 
the CRPC or 
the 
treatment 
naïve 
population 
68Ga-PSMA-11 
 
Ahmadzadehfar [6] 2017 32 Patients who were staged with PSMA-PET-CT before 223-Ra-dichloride were 
more likely to respond compared to patients without prior PSMA-PET-CT 
Retrospective 
cohort study, 
confounding 
very likely 
68Ga-PSMA-11 
 
Ferdinandus[7] 2017 40 Several clinicopathological variables but no PSMA-PET obtained variables were 
predictive for PSA response during 177Lu-PSMA therapy 
Retrospective 
cohort study, 
confounding 
very likely 
68Ga-PSMA-11 
PSMA-PET for response assessment 
Seitz[8] 2017 16 Outcome prediction was concordant between PSA response and PSMA-PET 
results in nine of 16 patients (56%) but only in four of 12 patients (33%) when 
assessed by CT 
Retrospective 
cohort study 
68Ga-PSMA-11 
Ahmadzadefar[6] 2017 32 PSMA-PET-CT could represent a better tool then PSA to assess treatment 
response after Ra-223-dichloride 
Retrospective 
cohort study 
68Ga-PSMA-11 
Bieth[9] 2017 31 PSMA-PET-CT images were used to calculate two new indices incorporating the 
percentage of bone volume (BPIVOL) and average SUV (BPISUV) 
Retrospective 
cohort study 
68Ga-PSMA-11 
PSMA-PET targeted metastasis-directed therapy in the oligometastatic setting 
Guler [10] 2017 10 No recurrences at irradiated sites, progression free survival of 0% at 12 months Retrospective 
cohort study 
68Ga-PSMA-11 
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